New drivers of oncology market - Yervoy, Zelboraf, Xalkori and Zytiga - assessed

15 September 2011

The cancer marketplace is going through a paradigm shift with new product launches and competitive promotion vying for patient treatment share. “The medical advances of the last decade are starting to bear fruit with some exciting products launches in markets with high unmet needs,” says Dan Winkelman a therapeutic class director in oncology at BioTrends, a Decision Resources company, announcing a new set of reports, providing insights on uptake of new products and their impact on market dynamics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical